HomeCompareNYWKF vs ABBV

NYWKF vs ABBV: Dividend Comparison 2026

NYWKF yields 305.34% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NYWKF wins by $1705.30M in total portfolio value
10 years
NYWKF
NYWKF
● Live price
305.34%
Share price
$0.66
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1705.40M
Annual income
$1,037,195,595.57
Full NYWKF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NYWKF vs ABBV

📍 NYWKF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNYWKFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NYWKF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NYWKF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NYWKF
Annual income on $10K today (after 15% tax)
$25,954.20/yr
After 10yr DRIP, annual income (after tax)
$881,616,256.23/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, NYWKF beats the other by $881,595,200.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NYWKF + ABBV for your $10,000?

NYWKF: 50%ABBV: 50%
100% ABBV50/50100% NYWKF
Portfolio after 10yr
$852.75M
Annual income
$518,610,183.66/yr
Blended yield
60.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NYWKF
No analyst data
Altman Z
4.5
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NYWKF buys
0
ABBV buys
0
No recent congressional trades found for NYWKF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNYWKFABBV
Forward yield305.34%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$1705.40M$102.3K
Annual income after 10y$1,037,195,595.57$24,771.77
Total dividends collected$1638.77M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NYWKF vs ABBV ($10,000, DRIP)

YearNYWKF PortfolioNYWKF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$41,234$30,534.35$11,550$430.00+$29.7KNYWKF
2$161,790$117,669.55$13,472$627.96+$148.3KNYWKF
3$604,608$431,492.88$15,906$926.08+$588.7KNYWKF
4$2,153,925$1,506,994.30$19,071$1,382.55+$2.13MNYWKF
5$7,322,164$5,017,463.74$23,302$2,095.81+$7.30MNYWKF
6$23,775,484$15,940,768.47$29,150$3,237.93+$23.75MNYWKF
7$73,814,146$48,374,377.96$37,536$5,121.41+$73.78MNYWKF
8$219,340,648$140,359,511.97$50,079$8,338.38+$219.29MNYWKF
9$624,490,689$389,796,195.57$69,753$14,065.80+$624.42MNYWKF
10$1,705,400,633$1,037,195,595.57$102,337$24,771.77+$1705.30MNYWKF

NYWKF vs ABBV: Complete Analysis 2026

NYWKFStock

NTG Clarity Networks Inc. provides telecommunications engineering, information technology, networking, and related software solutions worldwide. Its products include StageEM, an enterprise solution that covers project portfolio management, demand and capacity, analytic and dashboard, and decision-making using real-time data; Workflow Management solution, which enables organizations to design, deploy, execute, monitor, and analyze their business processes; Network Inventory Management solution that covers networks, services, and resources for organizations; and Partner Relationship Management solution, which covers the value chain of partnerships and enables vendors to manage their strategic partners. The company's products also include NTS Asset Management solution that tracks life-cycle of an inventory from acquisition to delivery to retirement; NTS Trouble Ticket Management, a module that manages customer and network trouble tickets and allows users to create their own type of trouble tickets; NTS Utility Billing solution, which manages utility billing needs; Mi-World, an m-Commerce application for mobile shopping; and Telco In A Box solution, a pre-integrated CRM, order management, fulfillment, and billing solution. In addition, the company offers VoWiFi, an app that enables voice in WiFi for smartphones and androids; Last Mile Delivery, a platform that manages delivery activities, such as order taking, fulfillment, and delivery; PROXBOX, an IoT solution that automates the update of inventory, manufacturing, and asset management over 3G cellular, WiFi, and ethernet; and end-to-end business solutions that enables business to be managed remotely through accessible dashboards. Further, it provides solution development, system integration, testing as a service, outsourcing, consulting, training, and smart cities/building services, as well as digital transformation and data migration services. The company was founded in 1992 and is based in Markham, Canada.

Full NYWKF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NYWKF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NYWKF vs SCHDNYWKF vs JEPINYWKF vs ONYWKF vs KONYWKF vs MAINNYWKF vs JNJNYWKF vs MRKNYWKF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.